026 年世界衛生大會（WHA）期間，台灣外交部與衛生福利部帶領台灣醫療團隊於瑞士日內瓦舉辦「台灣智慧醫療與健康產業展」，向國際展示台灣在創新醫療、智慧醫療與韌性醫療領域的研發成果與產業實力。
世延生醫（S&T Biomed）很榮幸作為韌性醫療領域代表廠商之一參與此次展出，展示 EarlyFound® MMP-1 口腔癌唾液檢測系列產品，包括應用於醫學檢驗實驗室之定量型 ELISA Kit，以及適用於第一線快速篩檢之 Rapid Strip Test。
透過非侵入式唾液檢測技術，世延生醫致力提供快速、便利且精準的癌症早期檢測方案。目前 EarlyFound® 系列產品已取得歐洲、澳洲、新加坡及多個東南亞國家的上市許可，逐步將台灣創新醫療技術推向全球市場。
未來，世延生醫將持續深化國際合作，與全球醫療夥伴共同推動癌症早期篩檢與預防醫學發展。
During the 2026 World Health Assembly (WHA), Taiwan’s Ministry of Foreign Affairs (MOFA) and Ministry of Health and Welfare (MOHW) led a delegation of Taiwan’s medical and healthcare companies to Geneva, Switzerland, showcasing Taiwan’s innovation and strengths in smart healthcare, medical technologies, and healthcare resilience.
S&T BioMed was honored to participate as one of the representative companies in the Resilient Healthcare section, presenting its EarlyFound® MMP-1 oral cancer saliva-based detection products, including the quantitative ELISA Kit for clinical laboratory testing and the Rapid Strip Test for frontline screening applications.
With its non-invasive saliva testing technology, S&T BioMed is committed to providing faster, simpler, and more accessible solutions for early cancer detection. The EarlyFound® series has received market approvals across Europe, Australia, Singapore, and several Southeast Asian countries, bringing Taiwan’s innovative medical technologies to the global healthcare market.
S&T BioMed will continue expanding international collaborations and working with global healthcare partners to advance early cancer screening and preventive healthcare.
souece（列舉）：
環球生技： https://news.gbimonthly.com/tw/article/show.php?num=86751 、 https://news.gbimonthly.com/tw/article/show.php?num=86751
衛福部：https://www.mohw.gov.tw/cp-7399-86320-1.html
外交部：https://www.facebook.com/share/v/1CkTyZCTjh/ 、 https://www.mofa.gov.tw/News_Content.aspx?n=95&sms=73&s=122305